Literature DB >> 21487041

Transcriptional control of cellular metabolism by mTOR signaling.

Jessica L Yecies1, Brendan D Manning.   

Abstract

Tumor cells are characterized by adaptations in cellular metabolism that afford growth and proliferative advantages over normal cells and, thus, contribute to cancer pathophysiology. There is an increasing appreciation of the fact that oncogenic signaling controls the metabolic reprogramming of cancer cells; however, the mechanisms and critical players are only beginning to be elucidated. Recent studies have revealed that mTOR complex 1 (mTORC1), a master regulator of cell growth and proliferation downstream of oncogenic signaling pathways, controls specific aspects of cellular metabolism through the induction of metabolic gene expression. mTORC1 activation is sufficient to promote flux through glycolysis and the oxidative branch of the pentose phosphate pathway, as well as to stimulate de novo lipogenesis, all processes that are important in tumor biology. As mTORC1 signaling is aberrantly elevated in the majority of genetic tumor syndromes and sporadic cancers, this pathway is poised to be a major driver of the metabolic conversion of tumor cells. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487041      PMCID: PMC3693464          DOI: 10.1158/0008-5472.CAN-10-4158

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis.

Authors:  Shijie Li; Michael S Brown; Joseph L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

Review 2.  Common corruption of the mTOR signaling network in human tumors.

Authors:  S Menon; B D Manning
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

3.  Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.

Authors:  Umut Ozcan; Lale Ozcan; Erkan Yilmaz; Katrin Düvel; Mustafa Sahin; Brendan D Manning; Gökhan S Hotamisligil
Journal:  Mol Cell       Date:  2008-03-14       Impact factor: 17.970

4.  The pharmacology of mTOR inhibition.

Authors:  David A Guertin; David M Sabatini
Journal:  Sci Signal       Date:  2009-04-21       Impact factor: 8.192

Review 5.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

6.  GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice.

Authors:  Hélène L Kammoun; Hervé Chabanon; Isabelle Hainault; Serge Luquet; Christophe Magnan; Tatsuro Koike; Pascal Ferré; Fabienne Foufelle
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

7.  mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.

Authors:  David B Shackelford; Debbie S Vasquez; Jacqueline Corbeil; Shulin Wu; Mathias Leblanc; Chin-Lee Wu; David R Vera; Reuben J Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-18       Impact factor: 11.205

Review 8.  Molecular mechanisms of mTOR-mediated translational control.

Authors:  Xiaoju Max Ma; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-02       Impact factor: 94.444

Review 9.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

10.  ATP-citrate lyase links cellular metabolism to histone acetylation.

Authors:  Kathryn E Wellen; Georgia Hatzivassiliou; Uma M Sachdeva; Thi V Bui; Justin R Cross; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

View more
  80 in total

Review 1.  Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation?

Authors:  Asish K Saha; X Julia Xu; Thomas W Balon; Amanda Brandon; Edward W Kraegen; Neil B Ruderman
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

Review 2.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

3.  mTOR inhibitors for treatment of low-risk prostate cancer.

Authors:  Michael A Liss; Lanette Rickborn; John DiGiovanni; Dean Bacich; Linda A DeGraffenried; Manish Parihar; Ian M Thompson; Zelton Dave Sharp
Journal:  Med Hypotheses       Date:  2018-06-05       Impact factor: 1.538

Review 4.  A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways.

Authors:  Ana P Gomes; John Blenis
Journal:  Curr Opin Biotechnol       Date:  2015-01-03       Impact factor: 9.740

5.  TGF-β Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation.

Authors:  Erin M O'Leary; Yufeng Tian; Recep Nigdelioglu; Leah J Witt; Rengul Cetin-Atalay; Angelo Y Meliton; Parker S Woods; Lucas M Kimmig; Kaitlyn A Sun; Gizem A Gökalp; Gökhan M Mutlu; Robert B Hamanaka
Journal:  Am J Respir Cell Mol Biol       Date:  2020-11       Impact factor: 6.914

Review 6.  Rapamycin: one drug, many effects.

Authors:  Jing Li; Sang Gyun Kim; John Blenis
Journal:  Cell Metab       Date:  2014-02-06       Impact factor: 27.287

7.  mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.

Authors:  Jing Li; Sejeong Shin; Yang Sun; Sang-Oh Yoon; Chenggang Li; Erik Zhang; Jane Yu; Jianming Zhang; John Blenis
Journal:  Cancer Res       Date:  2016-05-17       Impact factor: 12.701

8.  Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.

Authors:  Justin T Babcock; Hoa B Nguyen; Yujun He; Jeremiah W Hendricks; Ronald C Wek; Lawrence A Quilliam
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

9.  PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.

Authors:  Akio Iwanami; Beatrice Gini; Ciro Zanca; Tomoo Matsutani; Alvaro Assuncao; Ali Nael; Julie Dang; Huijun Yang; Shaojun Zhu; Jun Kohyama; Issay Kitabayashi; Webster K Cavenee; Timothy F Cloughesy; Frank B Furnari; Masaya Nakamura; Yoshiaki Toyama; Hideyuki Okano; Paul S Mischel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

Review 10.  Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection.

Authors:  Ying-Chun Lo; Chen-Fang Lee; Jonathan D Powell
Journal:  Curr Opin Organ Transplant       Date:  2014-08       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.